Evidence map›Paper›PMID 41888443›Full record

ArticleCancer gene therapy2026

SPINK5 promotes sensitivity to cisplatin by inducing ferroptosis in head and neck carcinoma.

Hui Yao, Guanghao Zhu, Haopu Li, Jingjie Wang, Caiyun Zhang, Minhui Zhu

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hui Yao *Department of Otolaryngology, Head and Neck Surgery, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Guanghao Zhu *Department of Otolaryngology, Head and Neck Surgery, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Haopu Li *Department of Otolaryngology, Head and Neck Surgery, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Jingjie WangDepartment of Otolaryngology, Head and Neck Surgery, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
Caiyun ZhangDepartment of Otolaryngology, Head and Neck Surgery, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China. fshzhang2002@163.com.
Minhui ZhuDepartment of Otolaryngology, Head and Neck Surgery, Shanghai Changhai Hospital, The First Affiliated Hospital of Naval Medical University, Shanghai, China. zmh197915@163.com.ORCID http://orcid.org/0000-0002-3859-7506

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin resistance remains a major obstacle in treating head and neck squamous cell carcinoma (HNSCC). Understanding its regulatory mechanisms is critical for improving therapeutic outcomes. SPINK5 expression was analyzed using TCGA datasets and tissue microarrays. Functional assays, including CCK-8, Annexin V-FITC/PI, and ferroptosis-specific probes (FerroOrange, DCFH-DA), were performed in SPINK5-overexpressing and FTH1-silenced HNSCC cells. Transcriptomic data were processed using R packages, with GSEA/GSVA for pathway analysis. Xenograft models were used to evaluate in vivo cisplatin responses. SPINK5 was significantly downregulated in HNSCC and correlated with poor prognosis and lymph node metastasis. Overexpression of SPINK5 enhanced cisplatin sensitivity by inducing ferroptosis, characterized by elevated ROS and Fe²⁺ levels, independent of classical apoptosis pathways. Unsupervised clustering and transcriptomic analysis identified FTH1 as a key downstream target of SPINK5. Mechanistically, SPINK5 suppressed FTH1 expression, promoting ferroptotic cell death and improving cisplatin efficacy in vitro and in vivo. SPINK5 functions as a tumor suppressor and sensitizes HNSCC cells to cisplatin by regulating ferroptosis via FTH1 downregulation, highlighting a novel therapeutic axis to overcome chemoresistance.

Indexed as

CisplatinFerroptosisHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckAnimalsAntineoplastic AgentsCell Line, TumorDrug Resistance, NeoplasmFemaleFerritinsGene Expression Regulation, NeoplasticHumansMiceOxidoreductasesXenograft Model Antitumor AssaysAntineoplastic AgentsCisplatinFerritinsFTH1 protein, humanOxidoreductases

Identifiers

PMID41888443

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.